Heat Biologics Inc (HTBX) 4.13 $HTBX
Heat Biologics, Inc. Reports 2014 First Quarter Financial Results
Marketwire - 24 mins ago
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company"
(NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today its financial results for the first quarter ended March 31, 2014 and provided highlights of the Company's recent corporate progress and anticipated near-term milestones for its two lead product candidates, HS-110 (Viagenpumatucel-L) for the treatment of non-small cell lung cancer (NSCLC) and HS-410 (Vesigenurtacel-L) for the treatment of bladder cancer.
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Heat Biologics, Inc. Presents Proprietary Allogeneic Cell Line Antigen Screening Algorithm and Systematic Analysis of Combination Tumor Immunotherapy Preclinical Data at the 105th Annual Meeting of the American Association for Cancer Research
Marketwire - Wed Apr 09, 11:00AM CDT
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company" (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company presented results of two preclinical ImPACT Therapy based research studies at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held April 5-9, 2014 in San Diego.
Heat Biologics, Inc. Reports 2013 Fourth Quarter and Full Year Financial Results
Marketwire - Tue Apr 01, 6:35AM CDT
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company" (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today its financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of the Company's quarterly highlights and recent corporate developments and clinical trial progress for its two lead product candidates, HS-110 for the treatment of non-small cell lung cancer (NSCLC) and HS-410 for the treatment of bladder cancer.
Heat Biologics, Inc. to Present at the MaidStone Life Sciences Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, March 27, 2014
Marketwire - Wed Mar 26, 3:15PM CDT
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a corporate overview at the MaidStone Life Sciences LLC 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference on March 27, 2014 at 10:30 a.m. Eastern Time at the New York Academy of Medicine in New York City.
Trial Protocol Submission Lifts Heat Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 10:30AM CDT
Shares of Heat Biologics gained more than 8% to close the trading session on March 20 at $7.42 .
3 Stocks Under $10 Making Big Moves
at The Street - Fri Mar 21, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Heat Biologics, Inc. Submits Revised Protocol to FDA for Phase 2 Clinical Study of HS-110 for the Treatment of Non-Small Cell Lung Cancer
Marketwire - Wed Mar 19, 7:03AM CDT
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company has submitted its revised Phase 2 clinical trial protocol for its HS-110 product candidate to the U.S. Food and Drug Administration for the treatment of patients with non-small cell lung cancer (NSCLC). HS-110 is Heat's first product candidate in a series of its proprietary Immune Pan Antigen Cytotoxic Therapy ("ImPACT" based allogeneic cell lines designed to direct killer T cells to attack cancer. HS-110 utilizes genetically modified lung cancer cells to stimulate a patient's immune system to activate a robust cytotoxic T cell response against a wide array of lung cancer antigens. The Company also announced that it will host a live conference call and webcast with the investment community on March 20, 2014 at 11:00 a.m. ET to discuss this revised trial.
Heat Biologics, Inc. Presents Preclinical Data From Comparative Combination Cancer Immunotherapy Research Study at Keystone Symposia on Immune Evolution in Cancer
Marketwire - Mon Mar 10, 7:05AM CDT
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company will present the results of its preclinical research study entitled "Comparative Combination Cancer Immunotherapy with Vaccination and TNFRSF Stimulation" at the Keystone Symposia on Molecular and Cellular Biology: Immune Evolution in Cancer (X2) being held March 9-14, 2014 in Whistler, British Columbia.
Heat Biologics, Inc. Appoints Taylor H. Schreiber, M.D., PH.D. as Vice President of Research and Development
Marketwire - Wed Mar 05, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the appointment of Taylor H. Schreiber, M.D., Ph.D. as Vice President of Research and Development to lead the Company's ImPACT Therapy preclinical drug development research team. Dr. Schreiber is an expert the field of tumor immunology and co-inventor of significant elements of Heat's ImPACT Technology platform, with over 10 years of laboratory experience and ingenuity in the discovery of novel therapeutic immuno-oncology compounds.
Heat Biologics Commences Dosing of First Patient in Phase 1/2 Study of Novel Cancer Immunotherapy Product Candidate HS-410 for the Treatment of Bladder Cancer
Marketwire - Mon Mar 03, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the first patient has been dosed in its Phase 1/2 bladder cancer clinical study with product candidate, HS-410. HS-410 is an investigational biologic designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer. Dosing for the HS-410 Phase 1/2 study was initiated by clinical investigator Lawrence Karsh, M.D., F.A.C.S., at The Urology Center of Colorado in Denver.
Heat Biologics, Inc. Appoints Robert E. Corder, Ph.D. as Vice President of Manufacturing
Marketwire - Thu Feb 06, 6:35AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the appointment of Robert E. Corder, Ph.D. as Vice President of Manufacturing to lead Heat's ongoing manufacturing efforts. Dr. Corder brings to the Company over 20 years of global and U.S. expertise in bioprocess scale up, manufacturing and cGMP production for new vaccine candidates.
Heat Biologics, Inc. to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
Marketwire - Tue Feb 04, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a Company overview at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:00 a.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11, 2014 at the Waldorf Astoria in New York City.
Heat Biologics, Inc. Announces Formation of Clinical Advisory Board With Preeminent Immunotherapy and Oncology Experts
Marketwire - Mon Feb 03, 7:35AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the creation of a Clinical Advisory Board (CAB) to actively design and guide its clinical trials and the appointment of four leading oncologists to serve on this board. Justin Stebbing, M.D., Ph.D. will serve as Chairman of the CAB and chief medical advisor to Heat.
Heat Biologics, Inc. to Present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference on Tuesday, January 21, 2014
Marketwire - Fri Jan 17, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference on Tuesday, January 21, 2014 at 8:30 a.m. Eastern Time.
Heat Biologics, Inc. to Present at Biotech Showcase 2014
Marketwire - Tue Jan 07, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference on Tuesday, January 14, 2014 at 10:30 a.m. Pacific (1:30 p.m. Eastern) at the Parc 55 Wyndham - Union Square, San Francisco, CA.
Pipeline Progress at Heat Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 12:30PM CST
Heat Biologics announced that a phase I/II study on HS-410 is open for enrolment.
Heat Biologics Announces Its Phase 1/2 Study of HS-410 in Bladder Cancer Is Open for Enrollment
Marketwire - Mon Dec 30, 12:15PM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that its Phase 1/2 Study of HS-410 in bladder cancer patients is open for enrollment. HS-410 is a biologic product candidate designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer.
Heat Biologics, Inc. Reports 2014 First Quarter Financial Results
Marketwire - 24 mins ago
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company"
(NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today its financial results for the first quarter ended March 31, 2014 and provided highlights of the Company's recent corporate progress and anticipated near-term milestones for its two lead product candidates, HS-110 (Viagenpumatucel-L) for the treatment of non-small cell lung cancer (NSCLC) and HS-410 (Vesigenurtacel-L) for the treatment of bladder cancer. Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Heat Biologics, Inc. Presents Proprietary Allogeneic Cell Line Antigen Screening Algorithm and Systematic Analysis of Combination Tumor Immunotherapy Preclinical Data at the 105th Annual Meeting of the American Association for Cancer Research
Marketwire - Wed Apr 09, 11:00AM CDT
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company"
(NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company presented results of two preclinical ImPACT Therapy based research studies at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held April 5-9, 2014 in San Diego. Heat Biologics, Inc. Reports 2013 Fourth Quarter and Full Year Financial Results
Marketwire - Tue Apr 01, 6:35AM CDT
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company"
(NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today its financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of the Company's quarterly highlights and recent corporate developments and clinical trial progress for its two lead product candidates, HS-110 for the treatment of non-small cell lung cancer (NSCLC) and HS-410 for the treatment of bladder cancer. Heat Biologics, Inc. to Present at the MaidStone Life Sciences Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, March 27, 2014
Marketwire - Wed Mar 26, 3:15PM CDT
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a corporate overview at the MaidStone Life Sciences LLC 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference on March 27, 2014 at 10:30 a.m. Eastern Time at the New York Academy of Medicine in New York City.
Trial Protocol Submission Lifts Heat Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 10:30AM CDT
Shares of Heat Biologics gained more than 8% to close the trading session on March 20 at $7.42 .
3 Stocks Under $10 Making Big Moves
at The Street - Fri Mar 21, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Heat Biologics, Inc. Submits Revised Protocol to FDA for Phase 2 Clinical Study of HS-110 for the Treatment of Non-Small Cell Lung Cancer
Marketwire - Wed Mar 19, 7:03AM CDT
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company has submitted its revised Phase 2 clinical trial protocol for its HS-110 product candidate to the U.S. Food and Drug Administration for the treatment of patients with non-small cell lung cancer (NSCLC). HS-110 is Heat's first product candidate in a series of its proprietary Immune Pan Antigen Cytotoxic Therapy ("ImPACT"
based allogeneic cell lines designed to direct killer T cells to attack cancer. HS-110 utilizes genetically modified lung cancer cells to stimulate a patient's immune system to activate a robust cytotoxic T cell response against a wide array of lung cancer antigens. The Company also announced that it will host a live conference call and webcast with the investment community on March 20, 2014 at 11:00 a.m. ET to discuss this revised trial. Heat Biologics, Inc. Presents Preclinical Data From Comparative Combination Cancer Immunotherapy Research Study at Keystone Symposia on Immune Evolution in Cancer
Marketwire - Mon Mar 10, 7:05AM CDT
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company will present the results of its preclinical research study entitled "Comparative Combination Cancer Immunotherapy with Vaccination and TNFRSF Stimulation" at the Keystone Symposia on Molecular and Cellular Biology: Immune Evolution in Cancer (X2) being held March 9-14, 2014 in Whistler, British Columbia.
Heat Biologics, Inc. Appoints Taylor H. Schreiber, M.D., PH.D. as Vice President of Research and Development
Marketwire - Wed Mar 05, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the appointment of Taylor H. Schreiber, M.D., Ph.D. as Vice President of Research and Development to lead the Company's ImPACT Therapy preclinical drug development research team. Dr. Schreiber is an expert the field of tumor immunology and co-inventor of significant elements of Heat's ImPACT Technology platform, with over 10 years of laboratory experience and ingenuity in the discovery of novel therapeutic immuno-oncology compounds.
Heat Biologics Commences Dosing of First Patient in Phase 1/2 Study of Novel Cancer Immunotherapy Product Candidate HS-410 for the Treatment of Bladder Cancer
Marketwire - Mon Mar 03, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the first patient has been dosed in its Phase 1/2 bladder cancer clinical study with product candidate, HS-410. HS-410 is an investigational biologic designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer. Dosing for the HS-410 Phase 1/2 study was initiated by clinical investigator Lawrence Karsh, M.D., F.A.C.S., at The Urology Center of Colorado in Denver.
Heat Biologics, Inc. Appoints Robert E. Corder, Ph.D. as Vice President of Manufacturing
Marketwire - Thu Feb 06, 6:35AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the appointment of Robert E. Corder, Ph.D. as Vice President of Manufacturing to lead Heat's ongoing manufacturing efforts. Dr. Corder brings to the Company over 20 years of global and U.S. expertise in bioprocess scale up, manufacturing and cGMP production for new vaccine candidates.
Heat Biologics, Inc. to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
Marketwire - Tue Feb 04, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a Company overview at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:00 a.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11, 2014 at the Waldorf Astoria in New York City.
Heat Biologics, Inc. Announces Formation of Clinical Advisory Board With Preeminent Immunotherapy and Oncology Experts
Marketwire - Mon Feb 03, 7:35AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the creation of a Clinical Advisory Board (CAB) to actively design and guide its clinical trials and the appointment of four leading oncologists to serve on this board. Justin Stebbing, M.D., Ph.D. will serve as Chairman of the CAB and chief medical advisor to Heat.
Heat Biologics, Inc. to Present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference on Tuesday, January 21, 2014
Marketwire - Fri Jan 17, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference on Tuesday, January 21, 2014 at 8:30 a.m. Eastern Time.
Heat Biologics, Inc. to Present at Biotech Showcase 2014
Marketwire - Tue Jan 07, 7:05AM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference on Tuesday, January 14, 2014 at 10:30 a.m. Pacific (1:30 p.m. Eastern) at the Parc 55 Wyndham - Union Square, San Francisco, CA.
Pipeline Progress at Heat Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 12:30PM CST
Heat Biologics announced that a phase I/II study on HS-410 is open for enrolment.
Heat Biologics Announces Its Phase 1/2 Study of HS-410 in Bladder Cancer Is Open for Enrollment
Marketwire - Mon Dec 30, 12:15PM CST
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that its Phase 1/2 Study of HS-410 in bladder cancer patients is open for enrollment. HS-410 is a biologic product candidate designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer.
